POMDOCTOR Details Four-Tier Revenue Model and FY2025 Revenue of RMB399.9M Amid AI Pivot
POM sits 20% above its 52-week low of $0.5 on light trading volume (0.1× avg).
Summary
POMDOCTOR disclosed a four-tier revenue structure and FY2025 audited revenue of RMB399.9M, adding concrete details to its AI healthcare pivot announced in July. The company named specific pharmaceutical partners and outlined plans for AI-enabled chronic disease subscriptions and RWD services, but near-term financial distress remains a key risk.
Key Events · Earnings and Guidance · POM
-
Four-Tier Revenue Structure Unveiled
POMDOCTOR detailed a four-tier model: B2C basic healthcare services, AI-enabled chronic disease memberships, B2B enterprise/hospital services, and pharmaceutical RWS/RWD services. The B2C tier is operational; AI and RWD tiers are in development.
-
FY2025 Revenue of RMB399.9M
Audited net revenues rose to approximately RMB399.9 million (US$59.04 million) in FY2025, up from RMB342.6 million in FY2024 and RMB304.9 million in FY2023, providing a baseline for the strategic pivot.
-
Pharmaceutical Partnerships Named
The company disclosed existing commercial relationships with Jiangsu Hansoh Pharmaceutical, Xiamen Amoytop Biotech, Shenyang Sinqi Pharmaceutical, and Eddingpharm (Suzhou), supporting its pharmaceutical supply chain and potential RWD expansion.
-
AI and RWD Tiers Remain Aspirational
The AI-enabled chronic disease membership and RWS/RWD services are still in development with no disclosed revenue or launch timeline, representing future growth bets rather than current contributors.
Analysis · POM · Trade & Services
POMDOCTOR is fleshing out its July AI pivot with a concrete four-tier revenue structure and hard FY2025 numbers — RMB399.9M in revenue, up from RMB342.6M in FY2024. The company is trying to show it has a real operating base (B2C healthcare services) to fund its AI ambitions, while also naming specific pharma partners like Jiangsu Hansoh. This matters because the company is under severe financial stress — a going concern warning and delisting scare just months ago — and needs to convince investors its pivot isn't just a rebranding exercise. The new revenue details and partner names give the strategy more substance than prior press releases, but the AI and RWD tiers remain aspirational with no revenue yet.
At the time of this filing, POM was trading at $0.60 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.50 to $115.74. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.